Similarly, the 2022ICC, within AML and related entities, incorporated different categories of KMT2A-rearranged AML, including AML with KMT2A::MLLT3, AML with other KMT2A rearrangements, and MPAL with KMT2A rearranged [20]. The gene discussed is KMT2A; the disease is mixed phenotype acute leukemia.